BC
AXSM icon

Bridgefront Capital’s Axsome Therapeutics AXSM Stock Holding History

Bridgefront Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$274K Buy
+1,624
New +$281K 0.07% 412
2025
Q1 		– Sell
-10,555
Closed -$893K – 624
2024
Q4 		$893K Buy
+10,555
New +$971K 0.3% 79
2021
Q2 		– Sell
-9,257
Closed -$524K – 605
2021
Q1 		$524K Buy
+9,257
New +$651K 0.16% 215

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgefront Capital's AXSM Position: Q1 2026 in Review

Bridgefront Capital opened a new position in Axsome Therapeutics (AXSM) in Q1 2026: 1,624 shares worth $274K. The stake represents 0.07% of the portfolio and ranks #412 among its holdings. This is a return to the name: Bridgefront Capital previously reported a position in AXSM as recently as Q4 2024.

Bridgefront Capital first reported a position in AXSM in Q1 2021 and has held it in 3 quarters since. The position peaked at $893K in Q4 2024. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Bridgefront Capital held 1,624 shares of Axsome Therapeutics worth $274K as of Q1 2026.
  • Axsome Therapeutics was a new Bridgefront Capital position in Q1 2026.
  • Axsome Therapeutics made up 0.07% of Bridgefront Capital's portfolio in Q1 2026, its #412 holding.
  • Bridgefront Capital first reported a position in Axsome Therapeutics in Q1 2021 and has held it in 3 quarters since.
  • Bridgefront Capital's Axsome Therapeutics position peaked at $893K in Q4 2024.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Bridgefront Capital's 13F filing for Q1 2026, filed 15 May 2026.